Orchid Pharma
Orchid Pharma Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Orchid Pharma Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Orchid Pharma Ltd trades at a P/E of 225.89× and P/B of 3.61×.
Valuation
Profitability
Growth
Financial Health
Orchid Pharma Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Orchid Pharma Ltd, switchable between annual and quarterly views, consolidated or standalone.
Orchid Pharma Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹4,671.23 Cr and reported EPS of ₹4.06.
| Period | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 688 | 600 | 508 | 450 | 560 | 666 | 819 | 922 | 811 |
| Other Income | 20 | 17 | 24 | 15 | 9 | 19 | 31 | 27 | 35 |
| Total Income | 708 | 617 | 533 | 465 | 569 | 685 | 850 | 949 | 847 |
| Cost of Goods Sold (COGS) | 350 | 290 | 243 | 229 | 314 | 385 | 484 | 544 | 526 |
| Gross Profit | 338 | 310 | 265 | 222 | 246 | 281 | 335 | 378 | 285 |
| +Operating Expenses | 322 | 328 | 290 | 172 | 196 | 198 | 224 | 261 | 244 |
| EBITDA | 16 | -18 | -25 | 50 | 50 | 84 | 111 | 117 | 41 |
| +Non-Operating Expenses | 435 | 331 | 130 | 160 | 119 | 126 | 50 | 49 | 42 |
| Profit Before Tax (PBT) | -399 | 69 | -131 | -95 | -60 | 55 | 92 | 96 | 21 |
| +Tax Expense | -46 | — | — | — | — | — | -3 | -0 | -0 |
| Profit After Tax (PAT) | -353 | 69 | -131 | -95 | -2 | 46 | 92 | 100 | 21 |
| Earnings Per Share (EPS) | -39.65 | 7.80 | -32.11 | -28.55 | -0.48 | 11.35 | 18.17 | 19.65 | 4.05 |
| Diluted Shares Outstanding (Nos.) | 9 | 9 | 4 | 4 | 4 | 4 | 5 | 5 | 5 |
| +Additional Disclosures | 1,458 | 1,039 | 905 | 768 | 1,002 | 1,045 | 1,240 | 1,401 | 1,345 |
| Sales Growth % | — | -12.77 | -15.32 | -11.41 | 24.33 | 19.00 | 23.05 | 12.52 | -12.00 |
| YoY Sales Growth % | — | -12.77 | -15.32 | -11.41 | 24.33 | 19.00 | 23.05 | 12.52 | -12.00 |
| Material Cost % | 50 | 44 | 46 | 55 | 61 | 61 | 64 | 64 | 57 |
| Employee Cost % | 13 | 14 | 17 | 15 | 11 | 10 | 8 | 9 | 11 |
| Other Cost % | 34 | 41 | 40 | 23 | 24 | 20 | 19 | 19 | 19 |
| OPM % | 2 | -3 | -5 | 11 | 9 | 13 | 14 | 13 | 5 |
| Tax % | 12 | — | — | — | — | — | -3 | -0 | -1 |
| Profit Growth % | — | 119.68 | -288.84 | 27.33 | 97.95 | 2,473.84 | 98.99 | 8.13 | -79.38 |
| Gross Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Margin % | 0.00 | -0.00 | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Additional Fields | -118 | -148 | -151 | -59 | -37 | 29 | 77 | 83 | 6 |
Orchid Pharma segment analysis: revenue and profit mix.
Disclosed business segments at Orchid Pharma with their share of revenue and profit, switchable between consolidated and standalone reporting.
Orchid Pharma discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
Orchid Pharma Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy Orchid Pharma Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Orchid Pharma Ltd's investment case rests on 7 positive markers and 9 flagged concerns drawn from the latest reported filings.
What you're getting.
Orchid Pharma maintains a strong promoter holding of 69.84%, indicating significant insider confidence and a reduced risk of hostile takeovers, which suggests a commitment to long-term success and stability.
The company demonstrates a healthy operating profit margin (OPM) of 11.60%, reflecting efficiency in managing core operations and generating profits from its primary business activities effectively.
Orchid Pharma exhibits a very low debt-to-equity ratio of 0.14, signifying a conservative financial approach with manageable debt levels, enhancing resilience to economic downturns.
The Return on Equity (ROE) stands at 8.21%, showing the company's reasonable ability to generate profits from shareholder investments, indicating efficient capital utilization.
The broader Pharmaceuticals sector, where Orchid Pharma operates, is poised for growth due to increasing global healthcare expenditure and demand for new therapeutic solutions.
What can break it.
Orchid Pharma's latest quarterly profit shows a significant decline of -49.20%, raising concerns about earnings predictability and the company's ability to maintain consistent profitability in the near term.
The stock has experienced considerable volatility, with a 52-week high of ₹1998 and a low of ₹604, indicating substantial market risk and uncertainty surrounding its future performance.
The current Price-to-Earnings (PE) ratio of 42.50 is higher than the sector PE of 37.63, suggesting a potentially overvalued stock where future growth might be priced in aggressively.
Promoter holdings have significantly decreased from 89.96% in 2022 to 69.84% in 2025, which warrants monitoring as it could signal potential future dilution or changes in management's commitment.
The company reported a substantial quarterly sales decline of -29.20%, indicating potential challenges in revenue generation and market demand, which could impact future financial health.
What would change my mind.
Trim if P/E re-rates above 294. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Orchid Pharma Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Orchid Pharma Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
Orchid Pharma Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Orchid Pharma Ltd — derived from the live tape, not yesterday's close.
Orchid Pharma Ltd last traded at ₹917.1 with an intraday range of ₹847–₹935 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹917.10| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1128.40 | +211.30 | +23.04% |
| R3 | 1040.40 | +123.30 | +13.44% |
| R2 | 987.70 | +70.60 | +7.70% |
| R1 | 952.40 | +35.30 | +3.85% |
| PIVOT | 899.70 | -17.40 | -1.90% |
| CURRENT | 917.10 | — | — |
| S1 | 688.40 | -228.70 | -24.94% |
| S2 | 776.40 | -140.70 | -15.34% |
| S3 | 811.70 | -105.40 | -11.49% |
| S4 | 864.40 | -52.70 | -5.75% |
ORCHPHARMA is trading Above CPR, indicating Bullishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: 847 ~ 872.95
Trading Above opening range, showing Bullishness
Orchid Pharma Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Orchid Pharma Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Orchid Pharma Ltd stood at 27.9% of traded volume, against a 20-day average of 43.6%.
Orchid Pharma announcements: results, concalls, ratings, M&A.
Filings Orchid Pharma sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Orchid Pharma files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 98 documents below.
Investor Presentation
Orchid Pharma Limited has informed the Exchange about Investor Presentation
Analysts/Institutional Investor Meet/Con. Call Updates
Orchid Pharma Limited has informed the Exchange about Schedule of meet
Monitoring Agency Report
Monitoring Agency Report for Quarter - IV of financial year 2025-26, ended on March 31, 2026
Disclosure under SEBI Takeover Regulations
DHANUKA Laboratories Ltd has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India…
Action(s) taken or orders passed
Orchid Pharma Limited has informed the Exchange about Action(s) taken or orders passed
Investor decks & rating reports.
Investor Presentation
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation
Investor Presentation
Investor Presentation
Analysts/Institutional Investor Meet/Con. Call Updates
Orchid Pharma dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Orchid Pharma has declared, sequenced by announce and record date.
Orchid Pharma corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Orchid Pharma Ltd: business, sector, key facts.
What Orchid Pharma Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Orchid Pharma Ltd operates in the Healthcare, listed as NSE: ORCHPHARMA, BSE: 524372.
Orchid Pharma Limited is an Indian pharmaceutical company specializing in the development, production, and marketing of a diverse range of pharmaceutical products. Their core offerings encompass active pharmaceutical ingredients (APIs), bulk drugs, finished dosage formulations (FDFs), and nutraceuticals. This broad portfolio allows them to cater to various sectors within the pharmaceutical industry, demonstrating a robust and diversified business model.
Within their API portfolio, Orchid Pharma focuses on key therapeutic areas. A significant portion of their business involves cephalosporins, both oral and injectable forms, used extensively in treating bacterial infections. They also manufacture veterinary products and non-antibiotic APIs, expanding their reach into different animal health and human health applications. This strategic diversification minimizes reliance on any single product or market segment.
Orchid Pharma boasts a multi-therapeutic presence across several key medical areas. These include anti-infectives (a significant area given their cephalosporin expertise), anti-inflammatory drugs, central nervous system medications, and cardiovascular drugs. The addition of nutraceuticals showcases a strategic move into the growing health and wellness market. Their product range further extends to other oral and sterile formulations, covering a wide spectrum of healthcare needs.
Beyond their manufacturing and marketing activities, Orchid Pharma offers specialized services in new drug discovery systems and pharmaceutical research and development. This positions them not only as a producer but also as a valuable partner for other pharmaceutical companies seeking innovative solutions and development expertise. Their international presence is also noteworthy, with exports to approximately 40 countries, indicating a significant global reach and market penetration.
Established in 1992 and currently a subsidiary of Dhanuka Laboratories Limited, Orchid Pharma (formerly Orchid Chemicals & Pharmaceuticals Limited) has a long history in the industry. Based in Narsinghpur, India, the company's integrated approach combining API manufacturing, formulation development, and global marketing contributes to its position as a significant player in the Indian and international pharmaceutical markets.
Questions investors ask about Orchid Pharma Ltd (ORCHPHARMA).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Orchid Pharma Ltd (ORCHPHARMA)?
The current share price of Orchid Pharma Ltd (ORCHPHARMA) is ₹917.1. Today, the stock has gained by ₹71.15 (8.41%), trading in a range of ₹847 to ₹935. The stock opened at ₹847 with a trading volume of 4,96,587 shares.
02Is Orchid Pharma Ltd stock a good investment for long-term?
Orchid Pharma Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹4,671.23 crores, P/E ratio of 225.89, ROE of 0.00%, and ROCE of 8.07%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Orchid Pharma Ltd stock?
The 52-week high price of Orchid Pharma Ltd (ORCHPHARMA) is ₹0, while the 52-week low is ₹0. Currently trading at ₹917.1, the stock is Infinity% away from its 52-week low and -Infinity% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Orchid Pharma Ltd stock at the current price?
Whether to buy Orchid Pharma Ltd stock at ₹917.1 depends on multiple factors. The stock is currently trading with a P/E ratio of 225.89 and P/B ratio of 3.61. Today's performance shows a gain of 8.41%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Orchid Pharma Ltd and when is the next dividend?
Orchid Pharma Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹917.1, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Orchid Pharma Ltd?
Orchid Pharma Ltd's key financial metrics include: P/E Ratio: 225.89, P/B Ratio: 3.61, ROE: 0.00%, ROCE: 8.07%, Dividend Yield: 0.00%, EPS: ₹4.06, Book Value: ₹253.98, and Debt-to-Equity: 0.00. The company's market cap stands at ₹4,671.23 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Orchid Pharma Ltd stock performing today in the market?
Orchid Pharma Ltd stock opened at ₹847 and is currently trading at ₹917.1, showing a gain of ₹71.15 (8.41%). The intraday high is ₹935 and low is ₹847. The trading volume stands at 4,96,587 shares, indicating moderate market participation today.
08What is the P/E ratio of Orchid Pharma Ltd and what does it indicate?
Orchid Pharma Ltd has a Price-to-Earnings (P/E) ratio of 225.89, which means investors are willing to pay ₹225.89 for every ₹1 of earnings. With an EPS of ₹4.06, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Orchid Pharma Ltd (ORCHPHARMA) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs & Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- Other overvalued NSE stocksScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy